Natera Names Susan Gross, M.D., Chief Medical Officer
Natera, a leading innovator in prenatal genetic testing, today announced the addition of Susan Gross, M.D., as the company’s first chief medical officer. She brings to Natera more than 25 years of experience in the field of prenatal genetics. The addition of Dr. Gross reflects Natera’s focus on solidifying its technology leadership position and advancing a strong R&D pipeline for future innovation.
Dr. Gross is a professor of clinical obstetrics & gynecology and women’s health, pediatrics and genetics at the Albert Einstein College of Medicine in New York City, where she has served as a member of the faculty since 1994. She is also the founding director of Einstein’s Program for Jewish Genetic Health and the founder of the Human Genetics Laboratory at Jacobi Medical Center, which was developed to provide the underserved with equal access to state-of-the-art prenatal genetic services.
“Sue’s deep experience in clinical genetics and genomics, as well as her superb reputation in scientific research, make her an excellent addition to Natera’s leadership team,” said Matthew Rabinowitz, Ph.D., chief executive officer of Natera. “With Sue on board, we are well-equipped to tackle the company’s biggest objectives: influencing policy and practice guidelines at the major medical societies, shaping Natera’s pipeline of next-generation innovative products and developing research partnerships with the leading academic medical centers around the world.”
Dr. Gross said, “I have been carefully following the field of non-invasive prenatal diagnosis since its outset. There is no doubt that we are witnessing a watershed moment in perinatal medicine. I am privileged to join the Natera team and strongly believe that this is the company with the requisite science and technology to not only provide leading edge patient care at present but also well into the future.”
Dr. Gross received her medical degree from the University of Toronto, where she also completed a residency in obstetrics & gynecology and a fellowship in maternal-fetal medicine. She then completed a second residency in medical genetics at the University of Tennessee, Memphis. Dr. Gross is a fellow of the American College of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics (ACMG) and the Royal College of Surgeons of Canada (RCSC). Dr. Gross has sat on national guideline and policy committees for both ACOG and ACMG and has authored more than 60 peer reviewed publications and multiple book chapters.
Natera is a leading genetic testing company that has developed a proprietary bioinformatics-based technology to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama™, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.
Editor’s Note: Photograph available on request
Lena Evans, 212-845-4262
Solomon Moshkevich, 650-249-9090